Quick Answer
Bolt Biotherapeutics, Inc. reported Total Revenue of $7.70 million for the year ending 2025.
- Bolt Biotherapeutics, Inc. showed an increase of +0.1% in Total Revenue from 2024 to 2025.
- This data is from Bolt Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $164.0 thousand | Q2 2020: $67.0 thousand | Q2 2021: $0.00 | Q3 2021: $752.0 thousand | Q1 2022: $813.0 thousand | Q2 2022: $1.39 million | Q3 2022: $2.11 million | Q1 2023: $1.83 million | Q2 2023: $1.43 million | Q3 2023: $2.53 million | Q1 2024: $5.27 million | Q2 2024: $1.28 million | Q3 2024: $1.14 million | Q1 2025: $1.22 million | Q2 2025: $1.80 million | Q3 2025: $2.17 million.
- Over the full 6 years of available data (2020 to 2025), Bolt Biotherapeutics, Inc.'s Total Revenue has grown by 3,231.2%.
- Historical annual values: Fiscal year 2025: $7.70 million | Fiscal year 2024: $7.69 million | Fiscal year 2023: $7.88 million | Fiscal year 2022: $5.73 million | Fiscal year 2021: $1.26 million | Fiscal year 2020: $231.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: